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ABSTRACT
Background: Flavonoids are nutrients that exert anti-allergic effects. We investigated the preventative effect
of enzymatically modified isoquercitrin (EMIQ), a flavonoid, to relieve the symptoms of Japanese cedar pollino-
sis.
Methods: In a parallel-group, double-blind placebo-controlled study design, 24 subjects with Japanese cedar
pollinosis took 100 mg EMIQ or a placebo for 8 weeks, starting 4 weeks prior to the onset of pollen release.
Subjective symptoms, ADL scores and the usage of drugs were recorded daily, and the QOL score was ob-
tained every 4 weeks. Blood sampling was performed before and after the study to measure serum levels of
IgE and flavonoids.
Results: During the entire study period, ocular symptom + medication score for the EMIQ group was signifi-
cantly lower (p < 0.05) than that of the placebo group. When limited to the period, ocular symptom scores (p <
0.05, weeks 5―6), and ocular congestion scores (p < 0.05, weeks 5―6) for the EMIQ group was significantly
lower than that for the placebo group while other scores for the EMIQ group, such as ocular itching scores (p =
0.09, weeks 4―5), lacrimation scores (p = 0.07, weeks 5―6), and ocular congestion scores (p = 0.06, weeks 4―
5), all tended to be lower. However no significant differences were found in nasal symptoms between the two
groups. Serum concentrations of IgE were not significantly downregulated but the serum concentrations of
quercetin and its derivatives were elevated significantly by the intake of EMIQ.
Conclusions: Intake of the quercetin glycoside EMIQ proved to be effective for the relief of ocular symptoms
caused by Japanese cedar pollinosis.
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INTRODUCTION
The number of allergic patients suffering from aller-
gic rhinitis, asthma and atopic dermatitis, has been
increasing globally, with changes in environmental
factors, in the past few decades.1,2 Diet has also been
proposed as one of the environmental factors.3-7 Ac-
cording to the hypothesis, changes in intake of lipids
or antioxidant substances during the last two decades
are thought to have increased the prevalence of aller-
gic diseases andor to have worsened allergic symp-
toms. If this is the case, an appropriate daily intake of
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Fig. 1 Chemical structure of enzymaticaly modified isoquercitrin (EMIQ), quercetin, isorhamnetin and tamarixetin.
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lipids or antioxidants may reduce the onset of allergic
diseases or ameliorate allergic symptoms.
Flavonoids are abundant in plant foods and possess
antioxidant as well as anti-allergic activities.8 We have
demonstrated that flavonoids such as apigenin,
fisetin, luteolin, quercetin and kaemferol suppress
the production of Th2 cytokines and CD40 ligand ex-
pression in activated human basophils.9-11 In addition,
oral administration of astragalin, a kaemferol glu-
coside, showed a preventative and ameliorative effect
on dermatitis in an atopic-dermatitis mouse model,
NCNga.12,13 We therefore proposed that an appro-
priate intake of flavonoids might constitute a dietary
preventative or therapeutic strategy for allergic dis-
eases.14,15 Indeed, we have recently reported on the
therapeutic efficacy of enzymatically modified iso-
quercitrin (EMIQ), a quercetin glycoside, by means
of a randomized double-blind placebo-controlled trial,
on ocular symptoms in patients with Japanese cedar
pollinosis.16 During the pollen season in 2007, EMIQ
intake started from March 4, significantly suppressed
an exacerbation of ocular symptoms at the beginning
of April that was due to an increase in scattered cedar
pollen or cypress pollen. Here, we investigated the
preventative effect of EMIQ on symptoms in patients
with Japanese cedar pollinosis.
METHODS
PARTICIPANTS
Patients enrolled in the study were 24 adult patients
in Osaka Prefecture, who had been suffering from
Japanese cedar pollinosis and showed positive blood
IgE specific for Japanese cedar pollen. All participants
provided written informed consent. The study proto-
cols were approved by the Ethics Committee of
Osaka University.
STUDY DESIGN
A randomized, double-blind, placebo-controlled de-
sign was used for the trial. Enzymatically modified
isoquercitrin (EMIQ, San-Ei-Gen F.F. I. Inc.,
Toyonaka, Osaka, Japan)17 and placebo were sup-
plied in capsule form. Figure 1 shows the chemical
structure of EMIQ, which is a glycoside of quercetin.
EMIQ has been recognized as a food additive,17
found to be safe by many evaluation studies including
an acute toxicity study, 4-week toxicity study, 13-
week toxicity study, chroniccarcinogenic study18
and mutagenicity study (Ames assay), and its no-
observed-adverse-effect level (NOAEL) was esti-
mated at approximately 500 mgkgday. Since the ac-
ceptable daily intake for humans is thought to be 5
mgkgday, we selected 100 mg EMIQ for the study.
The EMIQ capsule contained 50 mg EMIQ plus corn
Efficacy of EMIQ on Pollinosis
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Table 1 Subject characteristics
EMIQPlacebo
1212Number of participants
36.1±10.337.6±9.0 Age (mean±SD)
Gender
910Male
3 2Female
Total IgE (IU/ml)
215±254167±212at the beginning
196±238145±158at the end
Specific IgE for cedar polen (RAST score)
3.3±1.03.3±0.6at the beginning
3.3±1.03.3±0.6at the end
starch, and the placebo capsule contained corn starch
only with identical appearance to the EMIQ capsule.
Patients were randomly assigned to the EMIQ
group or the placebo group and took one capsule
twice a day for 8 weeks from January 27 to March 22,
2008. In 2008, according to the regional records for
Osaka Prefecture, the onset of cedar pollen release
occurred on February 22 and the amount of pollen
showed a peak in mid- March.
Since EMIQ is used as an antioxidant in some com-
mercially available food products, participants were
prohibited from taking such products during this pe-
riod.
OUTCOME MEASUREMENTS
The severity of subjective symptoms was evaluated
by a scoring system based on the method by Okuda
et al.19 During the testing period, participants were
asked to record symptom scores and activities of
daily living (ADL) everyday for 10 weeks. Symptoms
were evaluated using the following scale: sneezing
and rhinorrhea (0: none, 1: 1―5 episodes, 2: 6―10 epi-
sodes, 3: 11―20 episodes, 4: >20 episodes), nasal ob-
struction (0: none, 1: mild, 2: moderate, 3: severe, 4:
violent), ocular itching (0: none, 1: mild and bearable,
2: severe but bearable, 3: unbearable), lacrimation (0:
none, 1: seldom, 2: sometimes, 3: always), and con-
gestion of conjunctiva (0: none, 1: little, 2: mild, 3: se-
vere). The ADL score ranged from 0 to 4, with 0: no
problem, 1: mild symptoms not causing difficulties
with ADL, 2: moderate symptoms with some difficul-
ties with ADL, 3: severe symptoms with major diffi-
culties with ADL, 4: critical symptoms. The total
symptom score was calculated as the sum of the total
nasal and ocular symptom scores. The total nasal
score was calculated as the sum of specific nasal
scores such as sneezing, rhinorrhea and nasal ob-
struction. The total ocular score was shown as the
sum of specific ocular scores including those of ocu-
lar itching, lacrimation and ocular congestion. Thus,
the range of these scores was 0―147week for the to-
tal symptom score, 0―84week for the total nasal
score, 0―63week for the total ocular score and 0―28
week for the ADL score. Participants were allowed to
take anti-allergic drugs and use ocular drops and na-
sal sprays, depending on the severity of symptoms,
but the usage of these drugs was recorded in the
symptom diary and was evaluated according to medi-
cation scores,19 defined by the Japanese Society of Al-
lergology, using the following scale: 0: none, 1: oral
antihistamines, oral histamine release inhibitors, na-
sal application of vasoconstrictor or anticholinergic
drugs, histamine release inhibitive ocular drops, 2: fo-
cal administration of steroids, 3: oral administration
of steroids. The total symptom plus medication score
was calculated as the sum of the total symptom score
and the medication score. The nasal symptom plus
medication was the sum of the nasal symptom score
and the medication score excluding the score for ocu-
lar drops. The ocular symptom plus medication score
was calculated as the sum of the ocular symptom
score and the medication score including the score
for oral drugs, ocular drops and nasal sprays of corti-
costeroids since it has been shown that intranasal
corticosteroids provide partial relief of ocular symp-
toms.20,21
The degree of quality of life (QOL) was assessed
by using the Japanese allergic rhinitis QOL question-
naire (JRQLQ)22 prior to and at the 4th and 8th week
of the study. The JRQLQ comprises questions about
rhinorrhea, sneezing, nasal obstruction, nasal and
ocular itching, lacrimation, general fatigue, irritabil-
ity, depression and difficulties with daily activities
such as working, housekeeping, studying, reading,
doing sports, going outdoors, sleeping and having
conversations.
BLOOD SAMPLING
Blood sampling was performed prior to and at the 4th
and 8th week of the study. Serum concentrations of
total IgE antibody and specific IgE for Japanese cedar
pollen were analyzed by Shionogi Biomedical Labora-
tories (Osaka, Japan). Serum levels of quercetin,
isorhamnetin and tamarixetin were measured by
HPLC as described elsewhere,23 after hydrolyzation
of the samples.
STATISTICAL ANALYSIS
Symptom scores were analyzed with two-way ANOVA
(analysis of variance) for repeated measurements
with multiple comparisons. The data of serum fla-
vonoids are expressed as the means ＋－ SE and
compared using a two-tailed Student’s t-test. In both
tests, probability (p) values of <0.05 were considered
to indicate a statistically significant difference.
RESULTS
CHARACTERIZATION OF PARTICIPANTS
Table 1 shows subject characteristics of the placebo
and EMIQ group. The baseline characteristics were
Hirano T et al.
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Fig. 2 Changes in total symptom ＋ medication score and total symptom score in the EMIQ (solid dots) and the 
placebo (circles) group. Each value is the mean ＋/－ SE. ＊ p＜ 0.05, ＊ ＊ p＜ 0.01, ＊ ＊ ＊ p＜ 0.001, ＊ ＊ ＊ ＊ p＜
0.0001 compared with the first week in each group.
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similar for the two groups, and all participants
showed positive serum IgE for Japanese cedar pollen.
The average of total IgE levels for the EMIQ and the
placebo groups were 215 IUml or 167 IUml, respec-
tively. There were no significant differences in age,
total IgE or sensitization to the cedar pollen between
the two groups.
SYMPTOM ASSESSMENT
Figure 2 shows changes in the total symptom plus
medication score and the total symptom score. Both
scores for the placebo and EMIQ groups gradually in-
creased until weeks 7―8 in accordance with an in-
crease in the cedar pollen count. The scores of the
EMIQ group were lower than those of the placebo
group during weeks 3―8, but there was no statistically
significant difference in the total symptom plus medi-
cation score and the total symptom score for the in-
tervention period between the two groups. The
changes in the total nasal symptom plus medication,
total nasal symptom, sneezing, rhinorrhea and nasal
obstruction scores are shown in Figure 3. Although
no significant differences were found in these scores
between the two groups, the ameliorative effect of
EMIQ on ocular symptoms showed a statistically sig-
nificant difference in the total ocular symptom plus
medication score during the whole intervention pe-
riod (p = 0.04) (Fig. 4). When limited to the period,
total ocular symptom scores (p < 0.05, weeks 5―6),
and ocular congestion scores (p < 0.05, weeks 5―6)
for the EMIQ group was significantly lower than that
of the placebo group while other scores for the EMIQ
group, such as the ocular itching scores (p = 0.09,
weeks 5―6), lacrimation scores (p = 0.07, weeks 5―6),
and ocular congestion scores (p = 0.06, weeks 4―5),
all tended to be lower. The changes in the QOL
score, ADL score and medication score are shown in
Figure 5. There were no differences in the QOL, ADL
and medication scores between the two groups.
All participants completed the study, and no side
effects, such as gastrointestinal symptoms, allergic
reactions, cardiovascular symptoms, were observed
during the entire period. The mean percentage of in-
take for the EMIQ and placebo groups was 96.9% and
97.8%, respectively.
BLOOD PARAMETERS
In a previous study in 2007 we measured trough val-
ues of serum quercetin concentrations before and af-
ter the study and found that there was no accumula-
tion of serum quercetin level after continuous daily
intake of 100 mg EMIQ for 8 weeks.16 In this study
we measured serum concentrations of quercetin and
its methylated products, such as isorhamnetin and
tamarixetin, at 2 hours after intake of EMIQ or pla-
cebo capsule at 4 and 8 weeks of the study (Fig. 6).
Indeed, after taking EMIQ, the concentrations of
these EMIQ-derived products were significantly ele-
vated while the quercetin concentration remained un-
changed and serum levels of isorhamnetin and
tamarixetin were below 1 ngml in the placebo
group. During this study, there was no significant
change in serum concentration of total IgE and spe-
cific IgE for Japanese cedar pollen in either group
(Table 1).
DISCUSSION
In this study we set out to determine whether the in-
take of quercetin glycoside EMIQ proved to be effec-
tive for the relief of ocular symptoms caused by Japa-
nese cedar pollinosis. Previously we found that oral
intake of EMIQ inhibited the exacerbation of ocular
Efficacy of EMIQ on Pollinosis
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Fig. 3 Changes in nasal symptom ＋ medication score, total nasal score, sneezing score, rhinorhea score and nasal 
obstruction score in the EMIQ (solid dots) and the placebo (circles) group. Each value is the mean ＋/－ SE. ＊ p＜0.05, 
＊ ＊ p＜0.01, ＊ ＊ ＊ p＜0.001, ＊ ＊ ＊ ＊ p＜0.0001 compared with the first week in each group.
Nasal symptom ＋ Medication score40
30
20
10
0
Intervention period
0―1 1―2 2―3 3―4 4―5 5―6 6―7 7―8 8―9 9―10
Week
＊
＊
＊＊
＊＊
＊＊
＊＊
＊＊＊
＊＊
＊＊＊＊
＊＊＊＊
＊＊＊
＊＊＊
＊＊＊＊
Sneezing score14
12
10
8
6
4
2
0
Intervention period
0―1 1―2 2―3 3―4 4―5 5―6 6―7 7―8 8―9 9―10
Week
Rhinorrhea score12
10
8
6
4
2
0
Intervention period
0―1 1―2 2―3 3―4 4―5 5―6 6―7 7―8 8―9 9―10
Week
＊
＊＊
＊
＊＊
＊＊
＊＊
＊＊
＊＊＊＊
＊＊＊
＊＊＊
＊＊＊
＊＊＊＊
Nasal symptom score40
30
20
10
0
Intervention period
0―1 1―2 2―3 3―4 4―5 5―6 6―7 7―8 8―9 9―10
Week
＊
＊
＊
＊＊＊＊
＊＊
＊＊＊
＊＊
＊＊＊＊
＊＊＊
＊＊＊
＊＊＊＊
＊
＊＊
＊
＊＊
＊＊
＊
＊＊
＊＊＊
＊＊＊
＊
＊
＊＊
＊
＊
Nasal obstruction score14
12
10
8
6
4
2
0
Intervention period
0―1 1―2 2―3 3―4 4―5 5―6 6―7 7―8 8―9 9―10
Week
＊
＊＊
＊
＊
＊＊
＊＊
＊＊
＊＊
＊＊ ＊＊＊
＊＊＊＊
＊
＊
EMIQ
placebo
Hirano T et al.
378 Allergology International Vol 58, No3, 2009 www.jsaweb.jp
Fig. 4 Changes in ocular symptom ＋ medication score, ocular total score, ocular itching score, lacrimation score and 
ocular congestion score in the EMIQ (solid dots) and the placebo (circles) group. Each value is the mean ＋/－ SE. ＊ p＜
0.05, ＊ ＊ p＜ 0.01, ＊ ＊ ＊ p＜ 0.001, ＊ ＊ ＊ ＊ p＜ 0.0001 compared with the first week in each group. Arow with #p＜ 0.05 
shows comparison between both groups in the same week.
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Fig. 5 Changes in QOL score, ADL score and medication score in the EMIQ (solid dots) and the placebo (circles) 
group. The data presented are the mean ＋/－ SE. ＊ p＜0.05, ＊ ＊ p＜0.01, ＊ ＊ ＊ p＜0.001, ＊ ＊ ＊ ＊ p＜0.0001 compared 
with the first week in each group.
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symptoms caused by exposure to either the cedar
pollen or cypress pollen but did not suppress nasal
symptoms.16 Since the number of participants was
small (10 persons in each group), the result was lim-
ited. In addition, the study started on March 4th in
2007 when participants already had nasal and ocular
symptoms and therefore it was conducted to examine
the therapeutic effect of EMIQ. In 2008, we investi-
gated whether EMIQ might exert a preventative ef-
fect to reduce symptoms. Indeed, the oral intake of
EMIQ inhibited ocular symptoms but not nasal symp-
toms, so the efficacy was reproducible. The reason(s)
why EMIQ suppressed ocular symptoms but not na-
sal symptoms is yet to be determined. It is possible
that the nasal allergic inflammation is more severe
than in the eye. If that is the case, higher doses of
EMIQ intake would reduce nasal symptoms. Alterna-
tively, although ocular and nasal symptoms are medi-
ated by immediate type allergic reaction, the inflam-
mation of rhinitis is considered to be more compli-
cated than that of conjunctivitis. In allergic rhinitis, it
was demonstrated that the blood vessels, nerves and
mucous glands as well as mast cells, eosinophils and
T cells play a role in the generation of nasal symp-
toms.24
Quercetin glycosides are the most abundant fla-
vonoids present in plant foods.8 The sugar moiety has
been shown to affect its solubility and absorption.25
For instance, it was reported that the peak concentra-
tion of quercetin, after intake of the quercetin mono-
glucoside known as isoquercitrin, was 20 times
higher, and that this flavonoid reached its target 10
times faster than the corresponding values for the
quercetin rutinoside known as rutin, and that absorp-
tion of isoquercitrin was far better than that of agly-
cone quercetin by itself.26,27 The presence of sugars
Hirano T et al.
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Fig. 6 Changes in serum concentrations of quercetin, and its methylated metabolites isorhamnetin and tamarixetin in 
the EMIQ (solid circle) and the placebo (circle) group. Each value is the mean ＋/－ SE. ＊ ＊ p＜0.01, ＊ ＊ ＊ p＜0.001, com
pared with the values at the beginning of the study in each group. Arow with #p＜0.05, ##p＜0.01, ###p＜0.001, shows 
comparison between both groups in the same week.
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in the flavonoids is therefore an important determi-
nant for their absorption. EMIQ is more soluble than
quercetin and isoquercitrin, and is expected to be the
highest absorptive flavonoid among these quercetin
derivatives. In a previous study, we measured serum
concentrations of quercetin and the trough value did
not increase in the EMIQ group, so that successive
intake of EMIQ for 8 weeks did not lead to an accu-
mulation of quercetin in the blood.16 Here, we
showed that the serum levels of quercetin and its ma-
jor metabolites, isorhamnetin and tamarixetin28 were
elevated at 2 hours after EMIQ intake and quercetin
concentration reached around 90 ngml, indicating
that EMIQ was indeed absorbed.
The ameliorative effect of EMIQ was found in ocu-
lar symptoms and was to a large extent mediated
through its anti-allergic, antioxidant29 or other activi-
ties.8 We have found that some kinds of flavonoids
possess novel anti-allergic activities: including api-
genin, fisetin, luteolin, quercetin and kaemferol
which suppress the expression of Th2 type (IL-4, IL-5
and IL-13),9,10 and CD40 ligand11 in basophils. In ad-
dition to these in vitro anti-allergic activities, numer-
ous studies with allergic animal models have recently
demonstrated that flavonoids exert preventative and
therapeutic effects by modifying Th2 type cytokine
expression and suppressing IgE elevation.12,13,30-35 In
a study performed in 2007, the serum levels of cytoki-
nes and chemokines before and after the study were
measured but no significant reduction in Th2 cytoki-
nes (IL-4, IL-5 and IL-13) or IgE concentration as a re-
sult of EMIQ intake was found.16 Similarly, in 2008,
the serum level of IgE was not specifically reduced
for the EMIQ group, indicating that systemic im-
Efficacy of EMIQ on Pollinosis
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mune responses were not modulated by EMIQ in-
take. On the other hand, the ferric-reducing antioxi-
dant power tended to increase, and one oxidized
product, oxidized LDL, decreased in the EMIQ
group, suggesting that the ameliorative effect of
EMIQ was due to its antioxidant activity. With regard
to the involvement of oxidant stress in the develop-
ment of allergic conjunctivitis, few sources have been
available. In a murine model of allergic conjunctivitis
oxidative stress generated by NAD(P)H oxidase was
reported to augment immediate-type hypersensitivity
reactions and pollen antigen-driven allergic conjuncti-
vitis.36 The serum concentration of quercetin at 2
hours after EMIQ intake reached around 90 ngml,
which was 0.3 μM. The IC50 value of quercetin for the
inhibition of IL-4 production by activated basophils
obtained from in vitro analysis was, however, 18.8
μM,10 and the IC50 value of quercetin for the inhibi-
tion of histamine or other chemical mediators release
in basophils or mast cells is reportedly 3―15 μM.37-40
Since other flavonoids are also obtained orally from
foods and teas in significant amounts,41 the possibility
remains that the effect of flavonoids may be mediated
through their anti-allergic activity. Recently the aryl
hydrocarbon receptor has been demonstrated to be a
regulator of Th17 and regulatory T cell development
and these T cells are known to modulate autoimmune
and allergic reactions.42 The exogenous ligands for
aryl hydrocarbon receptor are environmental toxins
including 2,3,7,8-tetrachlorodibenzo-p-dioxin and fla-
vonoids have shown to inhibit dioxin-induced activa-
tion of aryl hydrocarbon receptor even below 1 μM.43
Therefore, the effect of EMIQ on ocular symptoms is
possibly mediated by affecting T cell differentiation
through inhibition of the activation of aryl hydrocar-
bon receptor. Alternatively, it is possible that EMIQ
directly affects conjunctival residential cells including
epithelial cells, resulting in the suppression of allergic
conjunctivitis.
In the dietary hypothesis, it has been proposed that
diet is one of the environmental factors that contrib-
ute to an increase in the prevalence of allergic dis-
eases andor worsening of allergic symptoms.4-7 Fur-
thermore, an epidemiologic study found that a higher
intake of flavonoids was associated with a lower inci-
dence of asthma.44 In experimental models, oral ad-
ministration of flavonoids has been demonstrated to
prevent allergic diseases including asthma, anaphy-
laxis, food allergies and atopic dermatitis.12,13,30-35 All
these findings, in addition to ones reported here for
EMIQ, strongly suggest that an appropriate intake of
flavonoids can be a dietary means for the prevention
and treatment of allergic diseases.
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